US · WHWK · BIOTECHNOLOGY
Whitehawk Therapeutics Inc (WHWK) intrinsic value and stock valuation
$3.07as of 2026-11-21 · Mkt cap 235.39M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Whitehawk Therapeutics Inc DCF and intrinsic value
InvestorsCraft values WHWK with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from WHWK’s statements →
Whitehawk Therapeutics Inc Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2019–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $7.14M | $26M | $24.4M | $15.2M | $1.12M |
| Operating income | -$-114.4M | -$-67.46M | -$-71.93M | -$-62.68M | -$-111.22M |
| Net income | -$-20.6M | -$-63.69M | -$-65.77M | -$-60.51M | -$-110.09M |
| EPSd | -$-332.85K | -$-2.36M | -$-2.44M | -$-2.69M | -$-12.34M |
| Operating cash flow | -$-97.43M | -$-59.55M | -$-59.66M | -$-49.64M | -$-22.42M |
| Capital expenditure | -$-550K | -$-1.65M | -$-3.97M | -$-440K | -$-50K |
| Free cash flow | -$-97.98M | -$-61.2M | -$-63.63M | -$-50.08M | -$-22.47M |
| Total assets | $150.8M | $70.3M | $132.4M | $184.2M | $157.9M |
| Total debt | $0.00 | $830K | $1.27M | $1.66M | $600K |
| Net debt | -$-37.57M | -$-27.84M | -$-61.62M | -$-37.36M | -$-148.38M |
| Total equity | $136.3M | $52.5M | $105.2M | $158.4M | $136.4M |
| Cash and short-term investments | $145.7M | $47.2M | $108.8M | $172.6M | $149M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $7.14M | $26M | $24.4M | $15.2M | $1.12M |
| Cost of revenue | $760K | $54.1M | $51.7M | $34M | $19.7M |
| Gross profit | $6.38M | -$-28.07M | -$-27.38M | -$-18.78M | -$-18.55M |
| Research and development expenses | $91M | $51M | $48.9M | $32.7M | $19.7M |
| Selling, general and administrative expenses | $29.8M | $36.8M | $44.6M | $40.2M | $18.5M |
| Other expenses | $0.00 | -$-48.39M | -$-48.93M | -$-28.94M | $54.5M |
| Operating expenses | $120.8M | $39.4M | $44.6M | $43.9M | $92.7M |
| Cost and expenses | $121.6M | $93.4M | $96.3M | $77.9M | $112.3M |
| Interest income | $6.23M | $3.92M | $6.4M | $2.4M | $10K |
| Interest expense | $0.00 | $150K | $230K | $230K | $670K |
| Depreciation and amortization | $80K | $190K | $170K | $160K | $100K |
| Ebitda | -$-20.52M | -$-64.63M | -$-65.36M | -$-58.8M | -$-36.96M |
| Operating income | -$-114.4M | -$-67.46M | -$-71.93M | -$-62.68M | -$-111.22M |
| Total other income/expenses, net | $93.8M | $3.77M | $6.17M | $2.17M | $1.13M |
| Income before tax | -$-20.6M | -$-63.69M | -$-65.77M | -$-60.51M | -$-110.09M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-20.6M | -$-63.69M | -$-65.77M | -$-60.51M | -$-110.09M |
| Weighted average shares outstanding | $61.9M | $27M | $26.9M | $22.5M | $8.87M |
| Weighted average diluted shares outstanding | $61.9M | $27M | $26.9M | $22.5M | $8.92M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $145.7M | $47.2M | $108.8M | $172.6M | $149M |
| Net receivables | $0.00 | $5.9M | $5.49M | $1.86M | $0.00 |
| Inventory | $0.00 | $5.31M | $6.43M | $1.86M | $0.00 |
| Total current assets | $149M | $61.3M | $124.6M | $180M | $151.3M |
| Property, plant and equipment, net | $0.00 | $7.63M | $5.97M | $2.03M | $610K |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $3.81M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $1.82M | $9.03M | $7.84M | $4.21M | $6.64M |
| Total assets | $150.8M | $70.3M | $132.4M | $184.2M | $157.9M |
| Accounts payable | $920K | $2.16M | $5.9M | $3.52M | $6.44M |
| Short-term debt | $0.00 | $270K | $430K | $390K | $130K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $14.5M | $17.1M | $26.4M | $18.8M | $15.3M |
| Long-term debt | $0.00 | $560K | $830K | $1.27M | $470K |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $0.00 | $770K | $830K | $7.02M | $6.23M |
| Capital lease obligations | $0.00 | $830K | $1.27M | $1.66M | $600K |
| Total liabilities | $14.5M | $17.8M | $27.2M | $25.9M | $21.5M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-353.25M | -$-332.65M | -$-268.96M | -$-203.2M | -$-142.69M |
| Accumulated other comprehensive income (loss) | $120K | $20K | $30K | -$-120K | $0.00 |
| Total equity | $136.3M | $52.5M | $105.2M | $158.4M | $136.4M |
| Total investments | $108.1M | $18.6M | $46M | $133.5M | $0.00 |
| Total debt | $0.00 | $830K | $1.27M | $1.66M | $600K |
| Net debt | -$-37.57M | -$-27.84M | -$-61.62M | -$-37.36M | -$-148.38M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-20.6M | -$-63.69M | -$-65.77M | -$-60.51M | -$-110.09M |
| Depreciation and amortization | $80K | $190K | $170K | $160K | $100K |
| Stock-based compensation | $9.87M | $10.8M | $12M | $9.64M | $2.11M |
| Change in working capital | $1.93M | $3.72M | -$-3.27M | -$-5.04M | $3.96M |
| Accounts receivable | -$-1M | -$-410K | -$-3.63M | -$-1.86M | $14.2M |
| Inventory | $170K | $1.12M | -$-3.27M | -$-1.86M | $0.00 |
| Accounts payable | $3.92M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash provided by operating activities | -$-97.43M | -$-59.55M | -$-59.66M | -$-49.64M | -$-22.42M |
| Investments in property, plant and equipment | -$-550K | -$-1.65M | -$-3.97M | -$-440K | -$-50K |
| Acquisitions, net | $101.3M | $0.00 | $0.00 | $0.00 | $25.2M |
| Net cash used for investing activities | $11.9M | $25.2M | $83.2M | -$-132.89M | $25.2M |
| Common stock issued | $100M | $130K | $0.00 | $72.5M | $155M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | -$-4.41M |
| Net cash used for financing activities | $94.4M | $130K | $330K | $72.6M | $141.8M |
| Net change in cash | $8.9M | -$-34.22M | $23.9M | -$-109.91M | $144.5M |
| Cash at end of period | $37.6M | $28.7M | $63M | $39.1M | $149M |
| Operating cash flow | -$-97.43M | -$-59.55M | -$-59.66M | -$-49.64M | -$-22.42M |
| Capital expenditure | -$-550K | -$-1.65M | -$-3.97M | -$-440K | -$-50K |
| Free cash flow | -$-97.98M | -$-61.2M | -$-63.63M | -$-50.08M | -$-22.47M |
Line items
Line items
Line items
About Whitehawk Therapeutics Inc
Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.
- CEO
- David J. Lennon
- Employees
- 29
- Beta
- 0.77
Explore
Frequently asked questions
What is the intrinsic value of Whitehawk Therapeutics Inc (WHWK)?
Whitehawk Therapeutics Inc (WHWK) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is WHWK undervalued?
WHWK trades at a price of $3.07 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.